Phase 2 Study [resa]
randomized [resa]
enzastaurin [orch, phsu]
LY317615 [orch, phsu]
Lung Cancer [neop]
Prevention [topp]
former smokers [fndg]
Chemoprevention [topp]
Lung Cancer [neop]
Nutraceutical [food]
Anti-Inflammatory Agents [phsu]
Mixed [ftcn]
Benefit [qnco]
Novel [tmco]
Targeted [ftcn]
Agent [chvf]
Hold [idcn]
promise [idcn]
Efficacy [qlco]
Authors [prog]
Report [inpr]
Evaluated [ftcn]
enzastaurin [orch, phsu]
Protein Kinase C Inhibitor [phsu]
properties [qlco]
former smokers [fndg]
Methods [inpr]
Primary [qlco]
Objective [inpr]
Study [mnob]
Average [qnco]
Fraction [qnco]
Ki [gngm]
Cells [cell]
Ki [gngm]
Labeling Index [lbtr]
Bronchial Biopsy [diap]
specimens [sbst]
Collected [idcn]
treatment [ftcn]
participants [popg]
randomized [resa]
Receive [qlco]
months [tmco]
Daily [tmco]
Oral [spco]
enzastaurin [orch, phsu]
mg% [qnco]
placebo [topp]
Stratification [resa]
Based [ftcn]
Morphology [qlco]
History [ocdi]
Lung Cancer [neop]
Airway Obstruction [dsyn]
Investigations [hlca]
Rationale [idcn]
For [qlco]
Protein Kinase C [aapp, enzy]
Inhibition [menp]
Pathway [moft]
interrogation [gora]
Established [qlco]
Premalignant Lesion [neop]
Stage [tmco]
Lung Cancer [neop]
intent [qlco]
randomized [resa]
participants [popg]
Pretreatment [sbst]
post treatment [tmco]
Ki [gngm]
Labeling Index [lbtr]
enzastaurin [orch, phsu]
Group [idcn]
placebo [topp]
Group [idcn]
P NOS [aapp, imft]
Six [qnco]
participants [popg]
Discontinued [fndg]
enzastaurin [orch, phsu]
Including [ftcn]
participants [popg]
adverse events [fndg]
Including [ftcn]
Abdominal distension [fndg]
Deep Vein Thrombosis [dsyn]
Hyponatraemia [fndg]
Rash [dsyn]
participants [popg]
Discontinue [fndg]
Participant [popg]
placebo [topp]
Group [idcn]
Discontinued [fndg]
Study [mnob]
Noncompliance [fndg]
participants [popg]
Serious Adverse Event [fndg]
Bradycardia [patf]
Deep Vein Thrombosis [dsyn]
Hypotension [fndg]
Conclusions [idcn]
Authors [prog]
Knowledge [inpr]
Represent [acty]
Chemoprevention [topp]
Trial [resa]
Food and Drug Administration [hcro]
Approved [qlco]
Oral [spco]
Small [qnco]
Agent [chvf]
Primary Endpoint [irda]
Meet [idcn]
enzastaurin [orch, phsu]
TOLERABILITY [resa]
months [tmco]
participants [popg]
Suggestion [idcn]
Response [orga]
Subset Analysis [resa]
Restricted [ftcn]
Metaplastic [ftcn]
Dysplastic [patf]
lesions [fndg]
American Cancer Society [pros]
